Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ifeyinwa Osunkwo

Pediatrics Charlotte, NC Medical Doctor

NPI 1144266982 CMS profile 481389

1021 Morehead Medical Dr, Ste A, Charlotte, NC 28204

Open in the dashboard

General payments

$218,173

154 records reported · program years 2019–2024

Research payments

$13,916

Paid to them · 31 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$415,703 paid to institutions, not to them · program years 2019–2022

Through program year 2024, Ifeyinwa Osunkwo of Charlotte, NC is reported in the CMS Open Payments database as having received $218,173 across 154 general payments and $13,916 in research payments paid to them. Separately, studies naming them as principal investigator received $415,703 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $177 2
2022 General $29 2
2022 Research $186 1
2021 General $60,976 29
2021 Research $2,181 1
2020 General $40,112 26
2020 Research $10,491 25
2019 General $116,878 95
2019 Research $1,058 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ifeyinwa Osunkwo
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Ifeyinwa Osunkwo were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Ifeyinwa Osunkwo Pediatrics median Middle half National median
2019 $116,878 $86 $31–$183 $163
2020 $40,112 $49 $22–$110 $114
2021 $60,976 $68 $27–$158 $132
2022 $29 $77 $30–$173 $149
2023 $0 $88 $33–$190 $160
2024 $177 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $136,249 99 payments
  2. Global Blood Therapeutics, Inc. $38,964 34 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $12,580 1 payment
  4. Novo Nordisk Inc $7,457 2 payments
  5. Terumo BCT, Inc. $6,397 10 payments
  6. Emmaus Medical, Inc. $5,274 3 payments
  7. Pfizer Inc. $5,127 2 payments
  8. Chiesi USA, Inc. $5,000 1 payment
  9. Novartis Pharma AG $1,000 1 payment
  10. ViiV Healthcare Company $125 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $125,634 50 payments
  2. Consulting Fee $76,369 22 payments
  3. Travel and Lodging $13,036 38 payments
  4. Food and Beverage $3,102 43 payments
  5. Education $32 1 payment
Products named General payments · program years 2019–2024
  1. ADAKVEO $67,730 40 payments
  2. OXBRYTA Sickle Cell Disease $34,194 30 payments
  3. Spectra Optia Apheresis System $6,397 10 payments
  4. Endari $5,274 3 payments
  5. FERRIPROX $5,000 1 payment
  6. CRIZANILIZUMAB_ADAKVEO_HEMATOLOGY $1,000 1 payment
  7. AFINITOR $363 1 payment
  8. PROMACTA $334 6 payments
  9. OXBRYTA Hematology $52 1 payment
  10. KISQALI $25 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $13,916 31 payments

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record